Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,732 across all filing types
Latest filing 2023-03-14 Investor Presentation
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
112年03月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing of scheduled investor presentations and conference calls, including dates, times, locations, and links to presentation materials. It specifically mentions '法人說明會' which translates to 'investor presentation' or 'analyst briefing'. The content is focused on providing information about upcoming or past investor presentations rather than full financial reports or regulatory filings. The document length is short (1204 characters) and it contains presentation schedules and links to presentation PDFs, which aligns with the definition of an Investor Presentation (IP). There is no indication of full financial statements or detailed management discussion, so it is not an Annual Report or Interim Report. It is not a report publication announcement or regulatory filing since it contains substantive presentation information. Therefore, the best classification is Investor Presentation (IP).
2023-03-14 Chinese
本公司受邀參加瑞士信貸所舉辦之26th Credit Suisse Asian Investment Conference
Investor Presentation Classification · 90% confidence The document is a short announcement about the company (1795 美時) being invited to participate in the 26th Credit Suisse Asian Investment Conference. It provides details about the date, time, and location of the investor presentation and mentions that the company will explain its financial and operational status to institutional investors. The document does not contain actual financial statements or detailed financial analysis, but rather serves as a notice of an upcoming investor presentation event. The length is only 718 characters, indicating it is a brief announcement rather than a full report. Therefore, this document fits best under the category of Investor Presentation (IP).
2023-03-14 Chinese
111年第4季大陸投資
Regulatory Filings Classification · 95% confidence The document is a detailed tabular disclosure of investment amounts and related financial data concerning investments in mainland China by a Taiwanese listed company. It includes specific financial figures, investment methods, and regulatory limits. The content is structured as a regulatory disclosure rather than a full financial report or announcement. The document length is short (1443 characters), and it does not present a full annual or interim report, nor is it an announcement of a report publication. It is a regulatory filing providing specific investment information as required by authorities, fitting best under the category of Regulatory Filings (RNS).
2023-03-13 Chinese
112年2月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a listed company (美時) providing details about fund loans and endorsement guarantees for the current and previous months, including amounts and limits. It is a short report (632 characters) focused on specific financial data related to loans and guarantees, without broader financial statements or management discussion. It does not appear to be a full annual or interim report, nor an announcement of a report publication. The content fits best with a Regulatory Filing (RNS) as it is a regulatory disclosure of financial information that does not fit into other specific categories like Annual Report or Interim Report.
2023-03-10 Chinese
112年2月營業收入
Regulatory Filings Classification · 90% confidence The document is a revenue summary report for a company named 美時 for the period of February 2023 (民國112年02月). It contains monthly and cumulative revenue figures with percentage changes and explanations for revenue changes. The document is short (804 characters) and provides financial data but is not a full financial report. It appears to be a regulatory disclosure of revenue figures rather than a comprehensive financial report like an Annual Report (10-K) or Interim Report (IR). It is also not an announcement of a report publication but a direct disclosure of financial data. Given the nature of the content and the context of Taiwanese regulatory disclosures, this fits best under Regulatory Filings (RNS), which is a fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2023-03-10 Chinese
112年02月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, general managers, and other senior executives. It includes data on shares held, increases, decreases, and trust shares, with specific references to identities such as chairman, directors, and general manager. This type of document is characteristic of insider shareholding disclosures, which report personal share transactions or holdings by company directors and executives. There is no indication of financial statements, earnings data, meeting materials, or legal proceedings. The document is not a report publication announcement or a certification. Therefore, the document fits the category of Director's Dealing (DIRS). The document length is substantial and contains detailed insider shareholding data, supporting a high confidence in this classification.
2023-03-10 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.